27. February, 2026
Annual Report for 2025
Today, 27 February 2026, Cessatech publishes the Annual Report for 2025. 2025 was a...
2. February, 2026
Welcome to the first quarter of 2026
Welcome to the first quarter of 2026 2025 has been a year of significant...
2. December, 2025
Children deserve better prehospital pain treatment
A newly published registry study from the Region of Southern Denmark highlights a clear...
13. November, 2025
Financial Report Q3-2025
The Company has advanced well with its planned activities Closing the clinical and regulatory...
31. October, 2025
CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children
Successful completion of technology transfer of CT001 with STAQ Pharma supporting near term product...
21. August, 2025
Financial Report Q2-2025
The Company has advanced well with its planned activities Positive and clinical meaningful top-line...
14. August, 2025
Marketing Authorisation Application (MAA) for CT001 has been submitted to the European Medicines Agency (EMA) for acute pain management in children
The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency...
27. June, 2025
Cessatech Q&A – June company presentation
Selected top 5 summarized questions from investors… Q&A Cessatech_June
19. June, 2025
Strengthening Executive Management with the promotion of Martin Juhl
On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of...
11. June, 2025
Completion of the directed issue of shares
As announced on 28 May 2025, the Board of directors in Cessatech exercised an...
7. June, 2025
Paediatric pain in the ambulance is still being under-treated
When a child is in acute pain, minutes matter and so does the experience...
28. May, 2025
Positive top-line results from its final CT001 Study 0202
On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from...











